Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL By Ogkologos - December 12, 2024 585 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Breast Cancer Survivor Comes First Woman In The World To Give... June 17, 2020 FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma June 6, 2025 FDA Approves fam-Trastuzumab Deruxtecan-nxki for HER2-Low Breast Cancer August 24, 2022 Child Cancer Patient And His Dad Have A Little Fun When... October 3, 2019 Load more HOT NEWS WHO’s plans to create a ‘cervical cancer-free future’ Bean there done that: Can swapping to pulses be the new... Percentage of Cancer Patients Who Are Eligible for and Respond to... Prising open the trap: Getting to grips with targeted cancer drug...
